Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, specialty drug company Acura Pharmaceuticals has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Acura and see what CAPS investors are saying about the stock right now.
Palatine, Ill. (1935)
CEO Robert Jones (since 2011)
Return on Equity (average, past 3 years)
$29.3 million / $0
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 36% of the 97 members who have rated Acura believe the stock will underperform the S&P 500 going forward.
When is a non-catalyst a catalyst? ... There was never any doubt that Acura would be putting Nexafed on drugstore shelves, the issue has always been whether they will turn anything resembling a profit. The announcement [Monday] today changes absolutely nothing. OTC cold medicines are a pretty low margin business, and I suspect it takes having a hefty number of them to overcome the costs of doing business in the space. ... Nexafed will be priced similarly to branded pseudoephedrine, which means at the top of the tier, and provides no incentive for a buyer over generic pseudoephedrine.
Acura seems to attract a lot of pyramid-minded traders, who love to pile on once the stock gets some upward momentum because there are a lot of greater fools out there. Will they be the same greater fools who rode the share price back down from [$2.50] to [$1.40] after last month's irrational spike?
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Acura Is Poised to Pull Back originally appeared on Fool.com.
Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.